was climbing in early trading after the biopharmaceutical company said its pilot study for a new Parkinson's disease treatment showed positive effects in the first several weeks of treatment.
The company said its Neotrofin drug showed statistically significant results in improving patient scores on the "Motor Examination" test when compared to a placebo. The drug showed the most effectiveness in the first several weeks of treatment, when patients were given 250 milligrams twice a day. As the dosage was increased over the rest of the study to 500 milligrams twice a day and 1000 milligrams twice a day, the effectiveness of the drug decreased.
In a press release, NeoTherapeutics said, "The data from this study suggests that Neotrofin may have acute symptomatic benefits in patients with Parkinson's disease," but the company said it was surprised that the effects appeared so quickly and seemed to lessen during continued treatment.
NeoTherapeutics Vice President Jacob Huff said, "It is not clear whether the diminishing efficacy during the course of the study is due to loss of response with continuing treatment or to lower efficacy with higher doses." The company plans to discontinue the current study and instigate a new one keeping patients on lower doses throughout the course of the study.
Shares of NeoTherapeutics were climbing over 120% in to 60 cents after closing at 27 cents Thursday.